17 results
6-K
EX-99
BLRX
Bioline Rx Ltd
12 Oct 23
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide
7:14am
immunotherapies and biologics for oncology. Toward the company’s ultimate goal of improving accessibility, affordability, and availability for patients
6-K
EX-99.3
BLRX
Bioline Rx Ltd
3 Mar 14
Current report (foreign)
12:00am
recently adopted the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act
6-K
EX-99.3
BLRX
Bioline Rx Ltd
5 Mar 15
Current report (foreign)
12:00am
Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (collectively, the PPACA), important
424B2
BLRX
Bioline Rx Ltd
13 Jun 14
Prospectus for primary offering
12:00am
States.
The U.S. Congress recently adopted the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability
F-3
BLRX
Bioline Rx Ltd
30 May 14
Shelf registration (foreign)
12:00am
recently adopted the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act
20-F/A
adojb60xq42q
26 Mar 24
Annual report (foreign) (amended)
4:57pm
424B5
wb4xkk0ti kzmejz1pej
4 Mar 14
Prospectus supplement for primary offering
12:00am
424B5
3jw2n7lrnd6pezrhocoe
6 Feb 13
Prospectus supplement for primary offering
12:00am
424B5
kuj2 9yklnd
5 Mar 15
Prospectus supplement for primary offering
12:00am
424B5
ckqgd5
3 Mar 14
Prospectus supplement for primary offering
12:00am
424B5
9jcsbl
6 Mar 15
Prospectus supplement for primary offering
12:00am
20-F/A
02p3n9wxdx3xbibqo b3
23 Mar 15
Annual report (foreign) (amended)
12:00am
424B3
dx3y1b
8 Aug 13
Prospectus supplement
12:00am
- Prev
- 1
- Next